External open innovation partner programAstrazeneca’s Target Innovation Programme
AstraZeneca, through its Target Innovation Program, would like to enable your screening for the exploration and validation of attractive, novel drug targets, and novel mechanisms of modulating known targets. In this call we are focusing on chronic lung diseases (asthma, COPD, etc).
Phenotypic as well as molecular target screening proposals, and proposals for accessing fragment-screening libraries, are welcome.
The programme aims to foster innovative partnerships between AstraZeneca and novel science at academic or other research organizations, to advance target validation for your exciting new target ideas. Collaborative proposals can gain access to a diversity screening subset library of up to 250,000 compounds, phenotypic and fragment screening sets and/or the performance of a full high-throughput screen.
Applying under this programme is straightforward. A short online submission form will guide you in completing your proposal. While AstraZeneca will not share the information beyond its own staff, your proposal should contain only non-confidential information.
The submission should include:
- The therapeutic area
- Brief description of the target/pathway
- Screening proposal
- Proposed next steps to validate your approach
Each application is read and reviewed by experienced scientists who are committed to evaluate your proposals. You can expect to receive feedback within ten weeks of the submission of a proposal. Content of the initial proposals should be non-confidential. If you want to share confidential data or knowledge with us to further explain your proposal, please let us know in your application and we can if required set up appropriate arrangements after the initial review phase. The decision on which targets receive HTS access, and/or compound libraries is made at the sole and absolute discretion of AstraZeneca.
While AstraZeneca will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.
If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA) and to confirm ability to execute a Materials Transfer Agreement (MTA).
Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.
As a Swiss International company, Biowebspin has high standard security and privacy system. Biowebspin is in accordance with the Federal Data Protection and Information Commissioner. Check here the terms and conditions of the matchmaking service of Biowebspin.
AstraZeneca is a global, science-led biopharmaceutical company that spans the discovery, development, manufacturing, distribution and worldwide commercialisation of primary care and speciality care medicines.
Biowebspin is the leading life sciences network with more than 2 million researchers in Biotech, Pharma and Medtech. Biowebspin has a database of 50,000 companies working on 5000 different R&D projects in more than 50 topics, organized in 8 main types of partnering programs with Academia.